Immix Biopharma | Investor Presentation Deck | 58 slides · page 56 of 58
Highlights NXC-201's lower fludarabine dose and Carvykti's longer infusion window.
Pitch deck · comparison_table · compare_peers · balanced density
Slide locked Sign in to view
Slide schematic 3/3
source-note 1/1 table 1/1 title 1/1
Components 3
source-note data headline
Tools 1
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.